Study title: A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Behavior and Behavior Mechanisms [F01] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: DESMOPRESSIN | |||||
| ATC code: | |||||
| Document link: Desmopressin_ FE992026 CS022.pdf | |||||
| Document date: 2011-09-05 | |||||
| Study number: FE992026 CS022 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |